Profiles

Keywords
Last Name
Institution

Nancy Reau

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentInternal Medicine, Division of Digestive Diseases and Nutrition
AddressChicago IL 60612
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 15756529900.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Van J, Aloman C, Reau N. Potential Bias and Misconceptions in Liver Transplantation for Alcohol- and Obesity-Related Liver Disease. Am J Gastroenterol. 2021 Oct 01; 116(10):2089-2097. PMID: 34193797.
      View in: PubMed
    2. Fix OK, Blumberg EA, Chang KM, Chu J, Chung RT, Goacher EK, Hameed B, Kaul DR, Kulik LM, Kwok RM, McGuire BM, Mulligan DC, Price JC, Reau NS, Reddy KR, Reynolds A, Rosen HR, Russo MW, Schilsky ML, Verna EC, Ward JW, Fontana RJ. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology. 2021 08; 74(2):1049-1064. PMID: 33577086.
      View in: PubMed
    3. Kushner T, Reau N. Had Anyone Considered the Donors? Fertility and Pregnancy Outcomes Among Female Living Donors. Liver Transpl. 2021 09; 27(9):1235-1236. PMID: 34118122.
      View in: PubMed
    4. McGuire FH, André K, Bradsher ML, Harrison D, Sterling RK, Reddy KR, Serper M, Golin CE, Reau N, Lim JK, Nelson DR, Sarkar S, Evon DM. Willingness to participate in research among black patients with liver disease: A national cross-sectional study. J Viral Hepat. 2021 07; 28(7):982-993. PMID: 33665897.
      View in: PubMed
    5. L Volk M, Reau N. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: A Patient-Friendly Summary of the 2019 AASLD Guidelines. Clin Liver Dis (Hoboken). 2021 Feb; 17(2):85-89. PMID: 33680442.
      View in: PubMed
    6. Serper M, Evon DM, Amador J, Stewart PW, Sarkar S, Lok AS, Sterling RK, Reeve BB, Golin CE, Rajender Reddy K, Lim JK, Reau N, Nelson DR, Di Bisceglie AM, Fried MW. Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. Liver Int. 2021 04; 41(4):692-704. PMID: 33387381.
      View in: PubMed
    7. Kushner T, Reau N. Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy. J Hepatol. 2021 03; 74(3):734-741. PMID: 33248169.
      View in: PubMed
    8. Sulkowski M, Cheng WH, Marx S, Sanchez Gonzalez Y, Strezewski J, Reau N. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C. Adv Ther. 2021 01; 38(1):423-440. PMID: 33145648.
      View in: PubMed
    9. Dieterich DT, Bernstein D, Flamm S, Pockros PJ, Reau N. Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States. Aliment Pharmacol Ther. 2020 10; 52(8):1311-1322. PMID: 32813292.
      View in: PubMed
    10. Asselah T, Zeuzem S, Reau N, Hwang P, Long J, Talwani R, Robertson MN, Haber BA. Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis. Curr Med Res Opin. 2020 08; 36(8):1325-1332. PMID: 32459122.
      View in: PubMed
    11. Chaillon A, Wynn A, Kushner T, Reau N, Martin NK. Cost-Effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States. Clin Infect Dis. 2020 Apr 13. PMID: 32282879.
      View in: PubMed
    12. Do A, Reau NS. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatol Commun. 2020 Mar; 4(3):329-341. PMID: 32140652.
      View in: PubMed
    13. Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Reddy KR, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW. Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)". J Hepatol. 2020 03; 72(3):592-593. PMID: 31889556.
      View in: PubMed
    14. Chaillon A, Rand EB, Reau N, Martin NK. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. Clin Infect Dis. 2019 11 13; 69(11):1888-1895. PMID: 30689769.
      View in: PubMed
    15. Orekondy N, Cafardi J, Kushner T, Reau N. HCV in Women and Pregnancy. Hepatology. 2019 11; 70(5):1836-1840. PMID: 31135999.
      View in: PubMed
    16. Serper M, Evon DM, Stewart PW, Lok AS, Amador J, Reeve BB, Golin CE, Fried MW, Reddy KR, Sterling RK, Sarkar S, Di Bisceglie AM, Lim JK, Nelson DR, Reau N. Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. J Gen Intern Med. 2020 04; 35(4):1011-1020. PMID: 31659661.
      View in: PubMed
    17. Singal AK, Satapathy SK, Reau N, Wong R, Kuo YF. Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma. Dig Liver Dis. 2020 01; 52(1):98-101. PMID: 31582326.
      View in: PubMed
    18. Schwartz M, O'Brien C, Raya N, Reau N. Acquired Hemophagocytic Lymphohistiocytosis Associated With Disseminated Herpes Simplex Virus in Immunocompetent Host. ACG Case Rep J. 2019 Aug; 6(8):e00164. PMID: 31737703.
      View in: PubMed
    19. Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Rajender Reddy K, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol. 2019 09; 71(3):486-497. PMID: 31096006.
      View in: PubMed
    20. Kushner T, Cafardi J, Reau N. Considering direct-acting antivirals to cure hepatitis C virus during pregnancy: is this the last treatment frontier? Ther Adv Infect Dis. 2019 Jan-Dec; 6:2049936119838229. PMID: 30984395.
      View in: PubMed
    21. Ma K, Berger D, Reau N. Liver Diseases During Pregnancy. Clin Liver Dis. 2019 05; 23(2):345-361. PMID: 30947881.
      View in: PubMed
    22. Evon DM, Stewart PW, Amador J, Serper M, Lok AS, Sterling RK, Sarkar S, Golin CE, Reeve BB, Nelson DR, Reau N, Lim JK, Reddy KR, Di Bisceglie AM, Fried MW. A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. PLoS One. 2018; 13(8):e0196908. PMID: 30067745.
      View in: PubMed
    23. Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018 10; 68(4):1298-1307. PMID: 29672891.
      View in: PubMed
    24. Reau N. Pregnancy after liver transplantation: Can renal function quell the fear? Liver Transpl. 2018 05; 24(5):583-584. PMID: 29626391.
      View in: PubMed
    25. VanWagner LB, Reau N. Clinical Liver Disease: Introducing hot topics in hepatology. Clin Liver Dis (Hoboken). 2018 Feb; 11(2):33-34. PMID: 30147866.
      View in: PubMed
    26. Evon DM, Amador J, Stewart P, Reeve BB, Lok AS, Sterling RK, Di Bisceglie AM, Reau N, Serper M, Sarkar S, Lim JK, Golin CE, Fried MW. Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther. 2018 Apr; 47(7):1001-1011. PMID: 29377191.
      View in: PubMed
    27. Soriano V, Young B, Reau N. Report from the International Conference on Viral Hepatitis - 2017. AIDS Rev. 2018 Jan-Mar; 20(1):58-70. PMID: 29369303.
      View in: PubMed
    28. Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol. 2018 05; 68(5):895-903. PMID: 29221887.
      View in: PubMed
    29. Reau N, Robertson MN, Feng HP, Caro L, Yeh WW, Nguyen BT, Wahl J, Barr E, Hwang P, Klopfer SO. Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection. Hepatol Commun. 2017 10; 1(8):757-764. PMID: 29404492.
      View in: PubMed
    30. Reau N, Nelson DR. HBV reactivation after HCV eradication: Deja Vu. Liver Int. 2017 07; 37(7):1088. PMID: 28635166.
      View in: PubMed
    31. Reau NS. Pangenotypic regimens and the next generation hepatitis C virus therapy. Clin Liver Dis (Hoboken). 2017 Jun; 9(6):131-133. PMID: 30992976.
      View in: PubMed
    32. Reau N, Vekeman F, Wu E, Bao Y, Gonzalez YS. Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy. Hepatol Commun. 2017 07; 1(5):439-452. PMID: 29404471.
      View in: PubMed
    33. Kanwal F, Bacon BR, Beste LA, Brill JV, Gifford AL, Gordon SC, Horberg MA, Manthey JG, Reau N, Rustgi VK, Younossi ZM. Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. Gastroenterology. 2017 05; 152(6):1588-1598. PMID: 28442121.
      View in: PubMed
    34. Behara R, Reau N. Updates on hepatitis C virus therapy in the direct-acting antiviral era. Curr Opin Gastroenterol. 2017 May; 33(3):115-119. PMID: 28350558.
      View in: PubMed
    35. Evon DM, Golin CE, Stewart P, Fried MW, Alston S, Reeve B, Lok AS, Sterling RK, Lim JK, Reau N, Sarkar S, Nelson DR, Reddy KR, Di Bisceglie AM. Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. Contemp Clin Trials. 2017 06; 57:58-68. PMID: 28342989.
      View in: PubMed
    36. Tran TT, Ahn J, Reau NS. Corrigendum: ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol. 2016 11; 111(11):1668. PMID: 27808138.
      View in: PubMed
    37. Mikolajczyk AE, Farnan JM, McConville JF, Jensen DM, Reddy KG, Te HS, Reau N, Aronsohn AI. Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology. Hepatology. 2016 12; 64(6):2210-2218. PMID: 27506929.
      View in: PubMed
    38. Lawitz E, Reau N, Hinestrosa F, Rabinovitz M, Schiff E, Sheikh A, Younes Z, Herring R, Reddy KR, Tran T, Bennett M, Nahass R, Yang JC, Lu S, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Pearlman B, Shiffman M, Hawkins T, Curry M, Jacobson I. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology. 2016 11; 151(5):893-901.e1. PMID: 27486034.
      View in: PubMed
    39. Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, Patel K, Bräu N, Roberts SK, Afdhal N, Nader F, Henry L, Hunt S. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis. 2016 10 15; 63(8):1042-1048. PMID: 27444413.
      View in: PubMed
    40. Jensen DM, Sebhatu P, Reau NS. Generic medications for hepatitis C. Liver Int. 2016 07; 36(7):925-8. PMID: 27306302.
      View in: PubMed
    41. Shiffman ML, Rustgi V, Bennett M, Forns X, Asselah T, Vila RP, Liu L, Pedrosa M, Moller J, Reau N. Corrigendum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 07; 111(7):1077. PMID: 27356843.
      View in: PubMed
    42. Gaetano JN, Micic D, Aronsohn A, Reddy G, Te H, Reau NS, Jensen D. The benefit of paracentesis on hospitalized adults with cirrhosis and ascites. J Gastroenterol Hepatol. 2016 May; 31(5):1025-30. PMID: 26642977.
      View in: PubMed
    43. Shiffman ML, Rustgi V, Bennett M, Forns X, Asselah T, Planas Vila R, Liu L, Pedrosa M, Moller J, Reau N. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 06; 111(6):845-51. PMID: 27045929.
      View in: PubMed
    44. Desai AP, Reau N. The Burden of Rehospitalization for Patients With Liver Cirrhosis. Hosp Pract (1995). 2016; 44(1):60-9. PMID: 26782133.
      View in: PubMed
    45. Tran TT, Ahn J, Reau NS. ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol. 2016 Feb; 111(2):176-94; quiz 196. PMID: 26832651.
      View in: PubMed
    46. Reau N, Fried MW, Nelson DR, Brown RS, Everson GT, Gordon SC, Jacobson IM, Lim JK, Pockros PJ, Reddy KR, Sherman KE. HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver Int. 2016 Apr; 36(4):488-502. PMID: 26509462.
      View in: PubMed
    47. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17. PMID: 26575258.
      View in: PubMed
    48. Teriaky A, Reau N. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. Clin Liver Dis. 2015 Nov; 19(4):591-604, v. PMID: 26466649.
      View in: PubMed
    49. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44. PMID: 25942724.
      View in: PubMed
    50. Janardhan SV, Reau NS. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? Hepat Med. 2015; 7:11-20. PMID: 25926761.
      View in: PubMed
    51. Sengupta S, Wroblewski K, Aronsohn A, Reau N, Reddy KG, Jensen D, Te H. Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start? Dig Dis Sci. 2015 Oct; 60(10):3130-5. PMID: 25742912.
      View in: PubMed
    52. Reau N. HCV testing and linkage to care: Expanding access. Clin Liver Dis (Hoboken). 2014 Aug; 4(2):31-34. PMID: 30992916.
      View in: PubMed
    53. Desai AP, Satoskar R, Appannagari A, Reddy KG, Te HS, Reau N, Meltzer DO, Jensen D. Co-management between hospitalist and hepatologist improves the quality of care of inpatients with chronic liver disease. J Clin Gastroenterol. 2014 Apr; 48(4):e30-6. PMID: 24100752.
      View in: PubMed
    54. Aronsohn A, Reau N, Jensen D. Preparing for the uncertain yet inevitable: off-label combinations of antiviral agents in hepatitis C virus. Hepatology. 2014 May; 59(5):1688-91. PMID: 24806752.
      View in: PubMed
    55. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014 Apr; 59(4):1246-9. PMID: 24493069.
      View in: PubMed
    56. Reau N. Finding the needle in the haystack: predicting mortality in pregnancy-related liver disease. Clin Gastroenterol Hepatol. 2014 Jan; 12(1):114-6. PMID: 23962550.
      View in: PubMed
    57. Satoskar R, Reau N. Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force. Hepatology. 2013 Jul; 58(1):422-7. PMID: 23460345.
      View in: PubMed
    58. Gaetano JN, Reau N. Hepatitis C: management of side effects in the era of direct-acting antivirals. Curr Gastroenterol Rep. 2013 Jan; 15(1):305. PMID: 23269576.
      View in: PubMed
    59. Nelson DR, Jensen DM, Sulkowski MS, Everson G, Fried MW, Gordon SC, Jacobson I, Reau NS, Sherman K, Terrault N, Thomas D. Hepatitis C virus: a critical appraisal of new approaches to therapy. Hepat Res Treat. 2012; 2012:138302. PMID: 23094146.
      View in: PubMed
    60. Desai AP, Reau N, Reddy KG, Te HS, Mohanty S, Satoskar R, Devoss A, Jensen D. Persistent spontaneous bacterial peritonitis: a common complication in patients with spontaneous bacterial peritonitis and a high score in the model for end-stage liver disease. Therap Adv Gastroenterol. 2012 Sep; 5(5):275-83. PMID: 22973414.
      View in: PubMed
    61. Mufti AR, Reau N. A pregnant patient with a positive hepatitis B surface antigen. Frontline Gastroenterol. 2013 Jan; 4(1):12-19. PMID: 28839696.
      View in: PubMed
    62. Te HS, Dasgupta KA, Cao D, Satoskar R, Mohanty SR, Reau N, Millis JM, Jensen DM. Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant. 2012 Nov-Dec; 26(6):826-32. PMID: 22554357.
      View in: PubMed
    63. Mufti AR, Reau N. Liver disease in pregnancy. Clin Liver Dis. 2012 May; 16(2):247-69. PMID: 22541697.
      View in: PubMed
    64. Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F, Jensen D. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol. 2012 Jun; 56(6):1276-82. PMID: 22314423.
      View in: PubMed
    65. Desai AP, Reau N. Naives, nonresponders, relapsers: who is there left to treat? Clin Liver Dis. 2011 Aug; 15(3):483-95. PMID: 21867932.
      View in: PubMed
    66. Reau N, Hamzeh FM, Lentz E, Zhou X, Jensen D. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb; 19(2):94-102. PMID: 22239499.
      View in: PubMed
    67. Reau N, Satoskar R, Te H, DeVoss A, Elsen C, Reddy G, Mohanty S, Jensen D. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 2011 Mar; 106(3):452-8. PMID: 21063395.
      View in: PubMed
    68. Aronsohn A, Reau N. Long-term outcomes after treatment with interferon and ribavirin in HCV patients. J Clin Gastroenterol. 2009 Aug; 43(7):661-71. PMID: 19448563.
      View in: PubMed
    69. Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008 Aug; 103(8):1981-8. PMID: 18796095.
      View in: PubMed
    70. Singh NA, Reau N. Management of hepatitis B virus. J Antimicrob Chemother. 2008 Aug; 62(2):224-8. PMID: 18480168.
      View in: PubMed
    71. Reau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis. 2008 Feb; 12(1):203-17, x. PMID: 18242505.
      View in: PubMed
    72. Reau N. Best of AASLD 2006. Gastroenterol Hepatol (N Y). 2007 Jan; 3(1):51-4. PMID: 21960777.
      View in: PubMed
    73. Sauk J, Jensen DM, Mohanty SR, Reau N, Reddy KG, Te HS. Lack of Efficacy of Pegylated Interferon Monotherapy for Hepatitis C in Patients With End-Stage Renal Disease on Dialysis. Gastroenterol Hepatol (N Y). 2006 Jul; 2(7):504-508. PMID: 28289353.
      View in: PubMed
    Reau's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description